VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PRAProAssurance Corporation
$25.00$1.3B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksPRAFinancials

ProAssurance Corporation (PRA) Financials

30Y historyFree accessUpdated daily

Underwriting profitability remains strained as evidenced by the combined ratio fluctuating significantly, peaking at 102.4% in 2025Q1, while top-line revenue continues to contract with a 2.0% decline in 2026Q1.

PRA Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Revenue1.08B1.1B1.13B1.13B1.1B1.08B886.86M1.01B877.08M858.12M875.98M768.4M848.34M732.64M722.73M725.93M692.07M672.68M562.59M706.07M737.6M647.95M794.55M535.84M402.1M382.56M222.59M208.2M193.6M160.7M139.3M
Revenue Growth %-3.16%-2.67%-0.2%2.6%2.45%21.26%-12.18%15.14%2.21%-2.04%14%-9.42%15.79%1.37%-0.44%4.89%2.88%19.57%-20.32%-4.27%13.84%-18.45%48.28%33.26%5.11%71.87%6.91%7.54%20.47%15.36%26.29%
Medical Costs & Claims541.83M665.42M874.87M935.31M909.94M862.85M772.01M869.25M697.71M564.91M531.61M490.27M363.08M224.76M179.91M298.71M356.1M347.61M311.88M457.75M549.7M530.16M690.57M543.58M442.57M369M040.2M33.5M33.9M25.7M
Medical Cost Ratio %50.2%60.6%77.55%82.74%82.59%80.23%87.05%86.07%79.55%65.83%60.69%63.8%42.8%30.68%24.89%41.15%51.45%51.67%55.44%64.83%74.53%81.82%86.91%101.45%110.07%96.46%0%19.31%17.3%21.1%18.45%
Gross Profit274.81M432.61M253.34M195.11M191.86M212.58M114.85M140.65M179.37M293.21M344.37M278.13M485.26M507.88M542.81M427.22M335.97M325.08M250.71M248.32M187.9M117.79M103.98M-7.74M-40.47M13.56M222.59M168M160.1M126.8M113.6M
Gross Margin %25.46%39.4%22.45%17.26%17.41%19.77%12.95%13.93%20.45%34.17%39.31%36.2%57.2%69.32%75.11%58.85%48.55%48.33%44.56%35.17%25.47%18.18%13.09%-1.45%-10.07%3.54%100%80.69%82.7%78.9%81.55%
Gross Profit Growth %-70.77%29.84%1.69%-9.75%85.1%-18.34%-21.59%-38.82%-14.86%23.82%-42.68%-4.45%-6.44%27.06%27.16%3.35%29.66%0.96%32.16%59.52%13.28%1442.93%80.87%-398.47%-93.91%32.49%4.93%26.26%11.62%22.94%
Operating Expenses268.94M360.54M190.26M234.26M198.08M65.97M331.9M169.45M150.35M164.58M168.17M149.28M223.25M110.72M146.85M12.63M3.29M6.32M2.32M11.98M11.07M8.93M6.51M-104.22M-91.25M2.59M222.59M0000
OpEx / Revenue %24.92%32.84%16.86%20.72%17.98%6.13%37.42%16.78%17.14%19.18%19.2%19.43%26.32%15.11%20.32%1.74%0.48%0.94%0.41%1.7%1.5%1.38%0.82%-19.45%-22.69%0.68%100%0%0%0%0%
Depreciation & Amortization9.87M13.69M17.75M26.02M38.06M37.25M21.38M18.66M21.25M28.8M32.79M36.22M39.59M35.83M37.57M35.69M26.67M19.66M16.57M16.09M18.83M24M27.03M23.51M15.04M11.85M6.33M6.4M3.2M3M200K
Combined Ratio %75.12%93.44%94.41%103.46%100.56%86.37%124.47%102.85%96.69%85.01%79.89%83.23%69.12%45.79%45.21%42.89%51.93%52.61%55.85%66.53%76.03%83.2%87.73%82%87.37%97.13%100%19.31%17.3%21.1%18.45%
Operating Income91.12M72.07M63.08M-39.15M-6.22M146.61M-217.06M-28.8M29.02M128.62M176.2M128.85M262M397.16M395.97M414.6M332.68M318.76M248.39M236.34M176.83M108.86M97.47M96.47M50.78M10.97M0168M160.1M126.8M113.6M
Operating Margin %8.44%6.56%5.59%-3.46%-0.56%13.63%-24.47%-2.85%3.31%14.99%20.11%16.77%30.88%54.21%54.79%57.11%48.07%47.39%44.15%33.47%23.97%16.8%12.27%18%12.63%2.87%0%80.69%82.7%78.9%81.55%
Operating Income Growth %-14.25%261.12%-529.81%-104.24%167.54%-653.56%-199.24%-77.43%-27%36.74%-50.82%-34.03%0.3%-4.49%24.62%4.37%28.33%5.1%33.66%62.43%11.69%1.03%89.98%362.95%--100%4.93%26.26%11.62%22.94%
EBITDA100.99M85.76M80.83M-13.13M31.85M183.85M-195.68M-10.14M50.28M157.42M208.99M165.07M301.6M432.99M433.54M450.29M359.35M338.42M264.96M252.43M195.66M132.86M124.49M119.98M65.83M22.82M0174.4M163.3M129.8M113.8M
EBITDA Margin %9.36%7.81%7.16%-1.16%2.89%17.1%-22.06%-1%5.73%18.34%23.86%21.48%35.55%59.1%59.99%62.03%51.92%50.31%47.1%35.75%26.53%20.51%15.67%22.39%16.37%5.96%0%83.77%84.35%80.77%81.69%
Interest Expense20.77M20.84M22.34M23.15M20.37M19.72M15.5M16.64M16.12M16.84M15.03M14.6M14.08M2.75M2.18M3.48M3.29M3.48M6.89M11.98M11.07M8.93M6.51M3.41M2.88M2.59M00000
Non-Operating Income-15.68M-20.84M-22.34M-23.15M-20.37M-19.72M-15.5M-16.64M-16.12M-16.84M-15.03M-14.6M-14.08M-2.75M-2.18M-3.48M-3.29M-3.48M-6.89M-11.98M-11.07M-8.93M-6.51M42.73M34.3M-2.59M6.33M0000
Pretax Income87.59M72.07M63.08M-39.15M-6.22M146.61M-217.06M-28.8M29.02M128.62M176.2M128.85M262M397.16M395.97M414.6M332.68M318.76M248.39M236.34M176.83M108.86M97.47M50.33M13.61M10.97M28.3M63.2M66.2M49.2M40.7M
Pretax Margin %8.12%6.56%5.59%-3.46%-0.56%13.63%-24.47%-2.85%3.31%14.99%20.11%16.77%30.88%54.21%54.79%57.11%48.07%47.39%44.15%33.47%23.97%16.8%12.27%9.39%3.38%2.87%12.71%30.36%34.19%30.62%29.22%
Income Tax22.21M21.15M10.33M-545K-5.81M2.48M-41.33M-29.81M-18.03M21.36M25.12M12.66M65.44M99.64M120.5M127.5M101.08M96.74M70.66M68.15M49.84M28.84M24.66M11.45M188K-2.85M4M16.5M17.7M11.7M9.6M
Effective Tax Rate %25.36%29.35%16.38%1.39%93.53%1.69%19.04%103.49%-62.13%16.61%14.26%9.82%24.98%25.09%30.43%30.75%30.38%30.35%28.45%28.84%28.19%26.49%25.3%22.75%1.38%-25.95%14.13%26.11%26.74%23.78%23.59%
Net Income65.2M50.91M52.74M-38.6M-402K144.12M-175.73M1M47.06M107.26M151.08M116.2M196.56M297.52M275.47M287.1M231.6M222.03M177.72M168.19M236.43M113.46M72.81M38.7M12.21M12.45M24.3M46.7M47.4M37.5M31.1M
Net Margin %6.04%4.64%4.68%-3.42%-0.04%13.4%-19.81%0.1%5.37%12.5%17.25%15.12%23.17%40.61%38.12%39.55%33.46%33.01%31.59%23.82%32.05%17.51%9.16%7.22%3.04%3.25%10.92%22.43%24.48%23.34%22.33%
Net Income Growth %54.14%-3.47%236.63%-9502.99%-100.28%182.02%-17602.69%-97.87%-56.13%-29%30.02%-40.89%-33.93%8.01%-4.05%23.96%4.31%24.93%5.67%-28.86%108.38%55.82%88.13%217.06%-1.95%-48.77%-47.97%-1.48%26.4%20.58%4.71%
EPS (Diluted)1.260.991.03-0.73-0.012.67-3.260.020.882.002.832.113.304.804.464.653.603.352.612.393.431.771.190.670.230.260.520.980.960.760.65
EPS Growth %50.35%-3.88%241.1%--100.28%181.9%-17626.88%-97.89%-56%-29.33%34.12%-36.06%-31.25%7.62%-4.09%29.17%7.46%28.35%9.21%-30.32%93.79%48.74%77.61%191.3%-11.54%-50%-46.94%2.08%26.32%16.92%4.84%
EPS (Basic)-0.991.03-0.73-0.012.67-3.260.020.882.012.842.193.324.824.494.703.653.382.722.553.691.891.250.670.240.260.520.980.960.760.65
Diluted Shares Outstanding51.81M51.67M51.27M52.79M54.14M54.06M53.91M53.84M53.75M53.61M53.45M55.02M59.52M62.02M61.83M61.68M64.35M66.3M68.72M71.65M69.85M65.82M63.97M60.78M52.51M48.53M46.66M47.98M49.38M49.67M48.22M

Key Metrics

Growth RegimeContracting
ProfitabilityStrained
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Social inflation and reserve volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Persistent Premium Contraction Trends

As reported in recent financial filings, ProAssurance has experienced a consistent decline in top-line revenue, with quarterly growth rates remaining negative for most of the last ten periods, including a 2.0% contraction in 2026Q1, suggesting a challenging environment for maintaining market share in medical professional liability.

The sustained revenue contraction appears to reflect a strategic pivot toward underwriting discipline rather than aggressive volume growth in a competitive pricing landscape. Investors should monitor whether this trend indicates a loss of core market share to larger, more diversified competitors or a deliberate exit from unprofitable segments.

Underwriting Profitability Remains Highly Volatile

Based on the provided income statement data, the combined ratio has fluctuated significantly, peaking at 102.4% in 2025Q1, which indicates that the company occasionally relies on investment income to offset underwriting losses rather than achieving consistent profitability through its core insurance operations alone.

The volatility in the loss ratio, which reached as high as 82.9% in early 2025, suggests that the company is struggling to price for the severity of medical malpractice claims. This inconsistency warrants further investigation into whether current pricing models are adequately accounting for the rising costs of legal settlements.

Reserve Development Uncertainty Clouds Earnings

According to the historical quarterly data, the company's operating income has shown extreme sensitivity to loss-related charges, with net income swinging from a $5.8 million loss in 2025Q1 to a $33.4 million profit by 2025Q4, highlighting the inherent instability of long-tail medical professional liability reserves.

The dramatic variance in quarterly net income suggests that prior-year reserve adjustments may be significantly impacting current-period results. Analysts should remain cautious, as these swings may mask underlying underwriting performance issues that are not immediately apparent in the headline revenue figures.

Social Inflation Threatens Long-Term Solvency

As indicated by the persistent pressure on operating margins, the company faces significant headwinds from social inflation, where rising jury awards in medical malpractice cases may continue to outpace premium increases, potentially eroding the capital base over the long term if underwriting discipline is not maintained.

The company's reliance on the Segregated Portfolio Cell structure may provide some insulation, but the core specialty P&C business remains vulnerable to unpredictable legal outcomes. Investors should monitor whether the current pricing environment is sufficient to cover the increasing severity of claims or if further reserve strengthening will be required.

PRA — Frequently Asked Questions

Quick answers to the most common questions about buying PRA stock.

What was ProAssurance Corporation's (PRA) revenue in 2025?

For fiscal year 2025, ProAssurance Corporation (PRA) reported total revenue of $1.10B. This represents a 688.2% increase compared to $139.3M in 1996.

Is ProAssurance Corporation (PRA) profitable?

ProAssurance Corporation (PRA) is profitable, generating $50.9M in net income for the fiscal year ending 2025 with a net profit margin of 4.6%.

What is ProAssurance Corporation's operating profit margin?

ProAssurance Corporation (PRA) reported an operating income of $72.1M, resulting in an operating profit margin of 6.6%. This margin reflects the operational efficiency of the business before interest and taxes.

What is ProAssurance Corporation's gross profit and gross margin?

ProAssurance Corporation (PRA) generated $432.6M in gross profit for the year, representing a gross profit margin of 39.4%. This demonstrates the company's core pricing power and production efficiency.